SCHEMBL17100682

SCHEMBL17100682

O=S(=O)(c1ccc(OC(F)F)cc1)N1CCN(c2nc(CCC(F)(F)F)no2)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
KDM2B Q8NHM5 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 1/20 0.39
GBA1 P04062 2/20 0.38
PTGDR Q13258 5/20 0.38
HSD11B1 P28845 2/20 0.37
TSHR P16473 1/20 0.36
APOBEC3A P31941 2/20 0.35
APOBEC3G Q9HC16 2/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
RAB9A P51151 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100956 0.90 LMNA (0.42) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100786 0.88 PKM (0.50) LMNASMN1; SMN2ALDH1A1KMT2AMAPT
SCHEMBL17100787 0.84 MEN1 (0.40) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100852 0.83 LMNA (0.42) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100728 0.83 LMNA (0.41) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100892 0.82 TSHR (0.45) LMNAALDH1A1KMT2AMEN1HSD11B1
SCHEMBL17100794 0.81 LMNA (0.44) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100859 0.80 ALDH1A1 (0.39) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100692 0.80 ALDH1A1 (0.41) LMNASMN1; SMN2ALDH1A1KDM2BKMT2A
SCHEMBL17100735 0.79 ALDH1A1 (0.44) LMNASMN1; SMN2ALDH1A1KDM2BPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT LMNA 760/4885SMN1; SMN2 11/4885ALDH1A1 482/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 748/4885SMN1; SMN2 11/4885ALDH1A1 561/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT LMNA 760/4885SMN1; SMN2 11/4885ALDH1A1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.